FDA grants Fast Track designation to Liquidia's YUTREPIA for SSc-related Raynaud's phenomenon
Liquidia plans to start the Phase 2a RE-WARM study in October 2026, within the fourth quarter timeframe cited in its announcement.
SEC filing
Latest
2 stories
Thursday, September 3
Wednesday, August 12
Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal study
Second-quarter 2026 results show continued YUTREPIA uptake and the start of the Re-Spire pivotal study for L606, alongside a fourth straight profitable quarter.
SEC filing